Featured Research

from universities, journals, and other organizations

Age-Related Macular Degeneration (AMD) In An Asian Population

Date:
August 1, 2008
Source:
American Academy of Ophthalmology
Summary:
AMD erodes and can eventually destroy the central vision needed for reading, driving, and other daily tasks. When AMD risk levels among racial and ethnic groups are compared, Caucasians are usually identified as at highest risk.

AMD erodes and can eventually destroy the central vision needed for reading, driving, and other daily tasks. When AMD risk levels among racial and ethnic groups are compared, Caucasians are usually identified as at highest risk.

Asians in particular have been assumed to have lower risk. Recently Ryo Kawasaki, MD, and colleagues compared the prevalence of early and late AMD in approximately 4,000 residents of Funagata, Japan, to the rate in white participants in the Australian Blue Mountains Eye Study (BMES); diagnostic definitions were identical in the two studies and age standardization enhanced data comparability. Importantly, the Funagata study is the first in a Japanese population to confirm a link between smoking and AMD prevalence.

The overall AMD prevalence rate in right eyes was 4.1 percent for the Funagata study, very close to the BMES rate of 4.4.percent. Prevalence of late AMD in men was also comparable for the two groups, 1.1 percent for Funagata participants and 1.2 percent for BMES, but was markedly different for the two groups of women: 0.3 percent and 2.1 percent, respectively. The authors note that these findings need to be confirmed by larger studies in Asian populations. Two earlier studies also found a higher prevalence of late AMD in Asian men, in contrast with most studies in Caucasians where rates are higher for women.

The authors think a key reason may be that 36.8 percent of the Funagata men smoked, but only 2.8 percent of the women. In the BMES study, 14.4 percent of women were smokers. While many Asian men smoke, the habit is less socially acceptable for women. "As smoking is a well-recognized, modifiable AMD risk factor, smoking cessation is an important public health measure to reduce AMD, particularly among Japanese men," Dr. Kawasaki says.

This research was published in the August issue of Ophthalmology.


Story Source:

The above story is based on materials provided by American Academy of Ophthalmology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Ophthalmology. "Age-Related Macular Degeneration (AMD) In An Asian Population." ScienceDaily. ScienceDaily, 1 August 2008. <www.sciencedaily.com/releases/2008/08/080801155124.htm>.
American Academy of Ophthalmology. (2008, August 1). Age-Related Macular Degeneration (AMD) In An Asian Population. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/08/080801155124.htm
American Academy of Ophthalmology. "Age-Related Macular Degeneration (AMD) In An Asian Population." ScienceDaily. www.sciencedaily.com/releases/2008/08/080801155124.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins